Biosimilars

Discover the landscape of Biosimilars in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and intelligence on Biosimilars, helping you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

FDA Approves AbbVie's Tavapadon as Juvmo for Parkinson's Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfoli
CompanyDrug

FDA Approves AbbVie’s Tavapadon as Juvmo for Parkinson’s Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfolio

The US Food and Drug Administration (FDA) announced that it has approved AbbVie's (NYSE: ABBV) tavapadon for the treatment of Parkinson's disease, under the brand name Juvmo. Regulatory Milestone ItemDetailAgencyUS…

Biokin Scores Triple NMPA Breakthrough Therapy Designation – BL-M07D1, BL-M05D1, and Iza‑Bren Recognized Across Biliary Tract and Gastric Cancers

Biokin Scores Triple NMPA Breakthrough Therapy Designation – BL-M07D1, BL-M05D1, and Iza‑Bren Recognized Across Biliary Tract and Gastric Cancers

Biokin's BL-M12D1 Wins NMPA Clinical Trial Approval – ADC Candidate to Be Evaluated as Monotherapy in Relapsed or Refractory Hematologic Malignancies

Biokin’s BL-M12D1 Wins NMPA Clinical Trial Approval – ADC Candidate to Be Evaluated as Monotherapy in Relapsed or Refractory Hematologic Malignancies

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Henlius Biotech Receives FDA Clearance for Phase I Trial of HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer

CompanyDrug

Henlius Biotech Secures European Commission Approval for Poherdy Biosimilar to Roche’s Perjeta

CompanyDrug

Shandong Boan Biotech Advances First-in-China Anti-CD25 Antibody BA1106 into Phase II NSCLC Trial in Combination with Nivolumab Biosimilar BA1104

Roche Q1 Sales Rise 6% Driven by Innovative Medicines as China Expansion and Diagnostics Recovery Offset Currency Headwinds
Company

Roche Q1 Sales Rise 6% Driven by Innovative Medicines as China Expansion and Diagnostics Recovery Offset Currency Headwinds

CompanyDrug

Mabwell Bioscience Secures Second NMPA Approval for Denosu, China’s First Xgeva Biosimilar, Expanding Indication to Bone Metastasis and Multiple Myeloma

CompanyDrug

Shanghai Henlius Biotech Launches Phase I Trial for HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer

CompanyDrug

Henlius Biotech Doses First Patient in Phase I Trial for HLX319, a Biosimilar to Roche’s Phesgo

Henlius Biotech Secures Two New NMPA Approvals for Hanlikang – Expands Rituximab Biosimilar into DLBCL Combination Therapies
CompanyDrug

Henlius Biotech Secures Two New NMPA Approvals for Hanlikang – Expands Rituximab Biosimilar into DLBCL Combination Therapies

Show More